Edgewise Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Hello. Welcome to this fireside chat with Edgewise Therapeutics. I'm Joe Schwartz from the SVB Securities' equity research team. It's my pleasure to be joined by Kevin Koch and Behrad Derakhshan, CEO and Chief Business Officer at Edgewise, respectively. Thanks so much for joining us.
Thanks, Joe.
Thanks, Joe. Good to be here.
Maybe we can have you guys start us off with a brief overview of your recent accomplishments and ongoing initiatives and upcoming catalysts for this year.
Yeah, that'd be great. I mean, so it was a really successful '22, I think, for the company. We completed our SAD/MAD 1b studies in Becker muscular dystrophy in '21. We, then in '22, decided to take a set
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
